Share This Page
Litigation Details for ESPERION THERAPEUTICS, INC. v. RENATA LIMITED (D.N.J. 2024)
✉ Email this page to a colleague
ESPERION THERAPEUTICS, INC. v. RENATA LIMITED (D.N.J. 2024)
| Docket | 2:24-cv-06017 | Date Filed | 2024-05-10 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Julien Xavier Neals |
| Jury Demand | None | Referred To | Cathy L. Waldor |
| Patents | 11,613,511; 11,760,714 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ESPERION THERAPEUTICS, INC. v. RENATA LIMITED
Details for ESPERION THERAPEUTICS, INC. v. RENATA LIMITED (D.N.J. 2024)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2024-05-10 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation summary and analysis for: ESPERION THERAPEUTICS, INC. v. RENATA LIMITED (D.N.J. 2024)
ESPERION THERAPEUTICS, INC. v. RENATA LIMITED (2:24-cv-06017) litigation summary and analysis
Espersion Therapeutics, Inc. and Renata Limited are in active patent litigation in the US District Court for the District of New Jersey under case number 2:24-cv-06017. The docket reflects a live dispute framed around IP protection for Esperion’s lipid management portfolio, with the procedural posture and asserted claims to be confirmed from the complaint, answer, and any claim chart or infringement contentions.
No further litigation-specific details (asserted patents, claims, filing dates of complaint/amended complaint, motions, Markman schedule, venue and presiding judge, or settlement status) are present in the provided information, so a complete and accurate litigation analysis cannot be produced.
What patents are asserted in Esperion Therapeutics v. Renata Limited (2:24-cv-06017)?
No asserted patent numbers, publication numbers, or expiration dates are available from the input provided. Without the complaint or the infringement contentions, the specific patent estate is not identifiable.
Which Esperion product and mechanism does the complaint target?
No drug name, NDA/ANDA/BLA linkage, or therapeutic indication is provided, so the target product cannot be determined.
Are method-of-use, formulation, or manufacturing patents at issue?
No claim categories (formulation, process, method-of-treatment, polymorph, salt, or particle-size/delivery) are available from the input.
When was the lawsuit filed and what is the current litigation posture?
The input provides only the case caption and docket number. It does not include:
- complaint filing date
- any amended complaint date
- answer date
- whether Renata filed a motion to dismiss or transfer
- any scheduling order
- any Markman/claim construction dates
- whether expert discovery has begun
- trial date status
A posture assessment would be incomplete without those docket facts.
What court and judge is assigned?
No judge assignment or related case history is included in the input.
Are there related cases or consolidated proceedings?
No consolidation or related dockets are included.
What do the claims and defenses likely center on in Esperion v. Renata?
A claim-and-defense mapping requires at minimum the asserted patent list and the claimed infringements. The input does not include:
- the asserted patent claims
- Renata’s noninfringement/invalidity arguments
- any inequitable conduct allegations
- any prosecution-history estoppel or prior art themes
- any design-around or carve-out positions
A litigation analysis without these facts would be speculative.
Does the case include a Paragraph IV or other FDA-specific challenge?
The case number alone does not identify whether it is an Orange Book patent dispute tied to FDA ANDA/Biologics litigation.
Is invalidity pleaded under 35 USC 102/103/112?
No invalidity grounds are present in the input.
Is there an eligibility or enforceability dispute?
No enforceability facts are provided.
How strong is the Esperion patent estate in this case?
Patent estate strength depends on:
- the asserted claims and claim construction risk
- file history and prior art proximity
- remaining term (expiration and any PTA/PTE)
- litigation history and prior rulings
- secondary considerations and commercial scope
No asserted patents, claim scope, or expiration data were provided.
What is the expected expiration timeline for the asserted patents?
Not computable from the provided information.
What is the litigation record of the same patent family?
Not available from the input.
What settlement risks or outcomes affect Renata’s generic or follow-on launch?
Settlement and launch timing depend on:
- any standstill or licensing agreement
- court-ordered discovery and injunction posture
- whether entry is enjoined or allowed under a negotiated term
- whether the case resolves before trial or after claim construction
No settlement terms, injunction decisions, or FDA launch linkage are included.
Is an injunction sought and what is the status?
No injunction request or hearing outcomes are provided.
What launch date or market entry scenario is at stake?
No FDA regulatory status, approval/notice dates, or launch milestones are included.
What generic entry risks exist for Renata if the case proceeds to trial?
Risk assessment requires:
- infringement likelihood by claim
- validity strength by asserted prior art
- enforceability and written description/enablement posture
- residual injunction exposure and carve-out opportunities
Those inputs are not present in the provided material.
How do design-arounds impact noninfringement theories?
Not available from the input.
What is the probability of an adjudicated noninfringement or invalidity ruling?
Not determinable without the asserted claims and defenses.
How does Esperion v. Renata compare with other Esperion patent litigations?
Comparison requires:
- common asserted patents
- shared defendants or parallel ANDA disputes
- differing claim focus and outcomes
No parallel case list or asserted-patent overlap is provided.
Which defendants are frequent competitors in Esperion’s patent space?
Not available.
Do the same patents drive most Esperion disputes?
Not available.
Orange Book status: what patents are listed for Esperion’s drug(s) and what is the exclusivity landscape?
Orange Book mapping requires:
- NDA numbers and Orange Book listing data
- patent list with expiry and regulatory exclusivity end dates
- whether the patents asserted are Orange Book listed for the specific NDA
None of those data points are included in the input.
What exclusivity periods end when?
Not provided.
Which listed patents align with this docket’s asserted claims?
Not provided.
Regulatory and FDA pathway question: does this case relate to an ANDA or 505(b)(2) submission?
A linkage requires FDA submission identifiers in the complaint:
- ANDA number
- applicant name (Renata Limited or its affiliates)
- reference listed drug and submission paragraph
- certification (IV, I, II, III)
No such identifiers are included.
Does the complaint target a particular NDA reference product?
Not available.
What FDA certification type is implicated?
Not available.
Key Takeaways
- The provided input only identifies the parties and the docket number 2:24-cv-06017.
- A complete litigation summary and analysis cannot be produced without the complaint and docket events.
- Asserted patents, claim scope, FDA linkage, motions, and any settlement or injunction posture are not identifiable from the information provided.
FAQs
- What does docket 2:24-cv-06017 cover in terms of patents or product claims?
- Is Esperion v. Renata a Paragraph IV case tied to an ANDA certification?
- What procedural milestones matter most for patent cases in the District of New Jersey?
- How do claim construction outcomes typically shift settlement leverage in Hatch-Waxman suits?
- Where can counsel usually extract asserted-patent lists and infringement theories for this case docket?
References
- Court docket entry for Esperion Therapeutics, Inc. v. Renata Limited, 2:24-cv-06017.
More… ↓
